Direct answer. Heart transplant rejection is immune injury to a donated heart. It can occur despite taking prescribed immunosuppression, and assessment may detect it before obvious symptoms. Cellular and antibody-mediated rejection need specialist interpretation and potentially different treatment. Keep surveillance appointments and contact the transplant team promptly about new symptoms or difficulty taking medicines.
- Rejection is an immune process, not proof that someone failed to look after the transplant.
- Cellular and antibody-mediated rejection are distinct clinical terms.
- Surveillance and investigation of new symptoms have different purposes.
- A biopsy or blood-test result needs interpretation alongside graft function and clinical context.
- Do not stop immunosuppression or create a rescue dose from an online guide.
- New breathlessness, fever, chest pain or persistent vomiting needs prompt advice.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Does adherence make rejection impossible? | NHSBT educational context | No; continue the individual surveillance plan. |
| Do all forms have identical treatment? | Selected clinical guidance | No; type, graft function and clinical stability matter. |
| Does one blood result settle AMR? | Conflicted specialist diagnostic framework | No; antibody and pathology findings need clinical interpretation. |
| Can home symptoms exclude rejection? | Surveillance and safety education | No negative symptom checklist clears the graft. |
| Are treatment effects independently ranked? | Original financial-chain limitations | No; attributed options are not clean comparative efficacy estimates. |
Confidence is high in the need for transplant-team assessment and continued surveillance. Diagnostic and treatment pathways are attributed specialist context; fully financially screened comparative effects were not established here. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Rejection of a donated heart and what the diagnosis means
The rejection diagnosis identifies immune injury to the donated heart. NHSBT distinguishes different forms rather than treating every episode as the same process. The next discussion should explain the actual finding and why it matters. Selected NHSBT rejection explanation.
This guide concerns rejection of a transplanted heart. It is separate from the original illness that led to transplantation, infection after surgery and routine wound recovery. Several problems may be considered during the same investigation; a symptom alone does not identify which is present.
The term should be tied to the actual finding. Ask whether the team is describing suspected rejection, a tissue diagnosis, an antibody finding, an episode needing treatment or a longer-term graft problem. These descriptions are useful for different decisions and should not be treated as interchangeable.
A rejection discussion should also avoid blame. Report practical barriers, missed medicines or side effects honestly so the team can address them. Continuing care is more useful than assuming that every new finding can be explained by one behavior.
Cellular rejection, AMR and late presentation
Cellular rejection involves immune cells; antibody-mediated rejection (AMR) involves antibody-related injury. In the selected ISHLT framework, AMR assessment combines tissue/pathology and clinical findings, with donor-specific antibodies providing supporting information. A positive antibody result alone is not a complete diagnosis or a home treatment rule. Selected 2023 diagnostic framework.
The same guideline describes varied AMR presentations and no single universally agreed treatment combination. Its framework is used for context, with relevant diagnostic-company and pharmaceutical author interests disclosed below. It does not provide an independently certified medicine ranking.
NHSBT’s long-term account notes that rejection can occur late, including when illness disrupts medicines, and AMR may first present later after transplantation. The individual plan therefore needs a contact route beyond the initial recovery period. Fixed biopsy schedules and reassuring rarity categories are not imported. Selected late-complication context.
A stable previous review is part of the history, not a guarantee about a new illness. When contacting the team, describe what changed and the actual medicines taken. Do not decide from elapsed time since surgery that rejection is impossible.
Specialist treatment decisions and graft assessment
NHSBT describes stronger immunosuppressive treatment for selected rejection episodes and distinguishes cellular from antibody-mediated treatment. Intravenous steroids are among its cellular-rejection examples; further specialist treatment may be needed. This article supplies no universal regimen, response promise or choice for an individual biopsy grade. Selected attributed treatment context.
The decision needs the confirmed or suspected process, the graft’s condition and the recipient’s overall stability. Ask why a change is proposed, what it is intended to achieve and how the team will assess the result. A drug name without this explanation is an incomplete care plan.
Investigation and treatment may need hospital care. Ask which symptoms should trigger emergency assessment and who will coordinate the next step. Do not wait for every test to be discussed at a routine appointment when the team has advised urgent review.
The recipient and caregiver need instructions for the exact current regimen. Do not adopt a higher dose, steroid course or antibody-directed treatment because another patient had it. Transplant-centre decisions include monitoring and other risks that a brief article cannot personalize.
Why supplement and lifestyle claims need separate evidence
No supplement regimen for preventing or treating heart-transplant rejection is established by this focused financial review. “Immune support,” an antioxidant mechanism or a changed blood marker does not establish graft protection. Such marketing should not replace the prescribed transplant plan.
NHSBT’s healthy-living education supports tailored discussion of diet, activity, smoking and other ongoing health needs. This guide does not turn those habits into a guarantee against rejection, or prescribe a post-transplant training schedule or food quota. Selected healthy-living context.
A clinician may recommend a nutrient for a separate deficiency or bone-health problem. Ask what the indication is and whether the exact product fits the whole medicine list. A supplement used for that purpose should not be described as an alternative anti-rejection medicine.
Surveillance, heart biopsy and interpreting results
Surveillance looks for problems during planned follow-up; investigation for new symptoms asks why the person is unwell now. NHSBT’s warning-sign page says some problems are detected through clinic tests and biopsies. Attending those reviews is therefore different from repeatedly checking an internet symptom list. Selected surveillance context.
Royal Papworth’s actual biopsy guide describes removing small pieces of heart muscle for microscopic examination, commonly from the right ventricle. Access is through a vein, with local anaesthetic and imaging guidance. This is a diagnostic procedure, not a treatment that removes rejection. Selected actual biopsy explanation.
Ask what the result means, whether the team considers rejection present and what else the report needs to be interpreted. A pathology term, antibody result or pumping-function measurement should not become a self-treatment threshold. Ask when and how results will be explained.
This source set does not financially clear every commercial diagnostic-assay or immunosuppressant trial. A test used in a specialist pathway is not automatically independently proven to replace every biopsy for every recipient. No brand selection or universal biopsy-avoidance claim is supplied.
Urgent symptoms, infection and biopsy harms
Promptly contact the transplant team about new breathlessness or chest pain, fever/shivering, vomiting, diarrhoea or feeling markedly unwell. These are warning signs requiring assessment, not a checklist that distinguishes rejection from infection. Do not wait for a particular symptom count. Selected transplant warnings.
Severe or persistent chest discomfort with breathing difficulty, sweating, sickness or faintness requires emergency help through local services. Tell responders about the transplant and current medicines; do not drive yourself or delay for an online interpretation. Selected emergency chest-pain guidance.
Immunosuppression also reduces the ability to fight infections. NHSBT explains that infections can affect several sites and may occur beyond immediate recovery. Do not treat a fever as proof of rejection or independently add antibiotics; the team must identify the problem. Selected infection context.
Biopsy harms include bleeding or vessel injury, rhythm disturbance and injury around the heart or nearby structures. The actual Papworth source also discusses consent and individual concerns. Its numerical risks, automatic blood-thinner/diuretic pauses and next-day activity rule are excluded here. Obtain current centre-specific instructions.
Medicine monitoring, St John’s wort and procedure preparation
NHSBT describes different medicine regimens between centres and advises reporting missed doses, side effects and difficulty remembering tablets. Some drugs require blood monitoring and can affect kidneys, glucose or blood-cell counts. This is selected safety context, not a complete medicine menu. Selected medicine review.
NCCIH’s checked warning identifies St John’s wort as able to weaken cyclosporine used after transplantation. Disclose mood, sleep, digestive and “heart health” preparations as well as prescriptions. No generic hours-apart interval clears such a combination. Selected interaction caution.
Before a biopsy or other procedure, the transplant and procedural teams should reconcile the exact medicine list. A leaflet’s general pause instruction is not your individualized prescription. Ask for written directions about preparation and the medicines needed afterward.
Avoiding self-treatment and confusing CAV with acute rejection
Avoid independently stopping anti-rejection medicine because of side effects or a worrying result. The useful response is to contact the transplant team with the problem so the regimen can be reviewed. Avoid compensating for uncertainty about a retained or missed dose with an invented extra dose.
Avoid using “chronic rejection” as though it always describes a new acute episode. NHSBT also uses that phrase for cardiac allograft vasculopathy, a longer-term transplant-vessel condition. Ask which finding the clinician is discussing. Selected CAV terminology.
Children, pregnancy/family planning, kidney disease and complex infection need their own current specialist review. Adult schedules and medicine-safety paragraphs cannot supply their clearance. If advice differs between teams, request reconciliation before making a change.
The individual transplant-centre contact and review plan
NHSBT’s home-care education describes receiving individual instructions for medicines, activity, food and recovery. Tell the centre about missed medicines, pain-management difficulties or other problems following the plan. Fixed recovery weeks or promised medicine reductions are not adopted here. Selected practical care context.
Keep the current medicine list, transplant contact route and review information available. Ask whom to call outside normal hours, how results will be discussed and which service handles a new symptom. Tell another treating clinician that you are a transplant recipient before a prescription or procedure.
This guide gives no immunosuppressant dose, rescue course, biopsy interval, antibody or drug-level threshold, taper or procedure-pause schedule. The useful outcome is an agreed transplant-team plan, with a way to obtain advice when health or medicine use changes.
Immune experiments versus clinical treatment
Immune-cell and animal models can investigate transplant injury but cannot prescribe treatment for a human biopsy or antibody result. Assay measurements also require clinical interpretation; a laboratory mechanism is different from proving fewer rejection events or better graft survival. No animal or in-vitro result establishes a supplement or rescue regimen here.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 23 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Rejection care involves transplant services, immunosuppressant manufacturers, biopsy/device providers and commercial blood-test businesses. Relevant guideline-author diagnostic/drug relationships remain explicit. Public institution funding and professional recommendations do not clear the original intervention or assay trials; their efficacy is not independently ranked here.
The clinical subject has no single corporate owner; medicines, devices and supplements have separate commercial ownership and financial interests. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHSBT rejection explanation and surveillance; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected rejection definition and type-specific treatment context. |
| NHSBT transplant warning signs; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected symptom reporting and surveillance context. |
| NHSBT selected long-term complication context; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected late-rejection, illness and long-term monitoring context. |
| NHSBT selected transplant-medicine roles and cautions; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected immunosuppressant handling, harms and review. |
| NHSBT selected care at home after transplantation; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected individualized medicine and recovery support. |
| NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected healthy-living support; no rejection prevention guarantee. |
| NHSBT selected infection explanation; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected immunosuppression/infection distinction; no antibiotic duration or rare-harm reassurance. |
| NHSBT cardiac allograft vasculopathy explanation; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Selected long-term vascular distinction. |
| ISHLT recipient guideline, 2023; actual141-page original and disclosures | Original printed e117 reports no document-development/preparation financial support; declares relevant Natera/CareDx grants/consulting and Novartis/Biotest drug relationships. Separate society routes below. Full contracts, every contributor and original-trial chains unclosed. | Multinational writing group; US professional-society publication. Foundation contact separately traced; society legal headquarters and each commercial backer/manufacturing chain unclosed. | Tier 3 expert guidance with documented relevant commercial author ties; independent efficacy excluded. | C provisional — actual selected clinical sections and disclosures read. Expertise and transparency support attributed checking; dated evidence, consensus and diagnostic/drug interests remain. No independent effect estimates or personal regimen. Role: Selected surveillance, antibody/pathology interpretation and variable AMR framework. |
| Royal Papworth actual12-page cardiac-biopsy guide, October2025 version2; internal review-date discrepancy | Separate provider: see own explicitly dated accounts. Exact leaflet budget, contributor payments and underlying-study finance unclosed; national NHS funding does not substitute. | United Kingdom; actual Royal Papworth address Cambridge Biomedical Campus, Cambridge, England. Local provider procedure context. | Tier 2 provider procedural education, provisional. | C provisional — actual12-page guide selected mechanism, consent and harms read. October2025 printing/2027 footer review conflicts with2025 consent-page review field. Specialist/service interests and financial gaps remain; no personal pause, procedure rate or recovery promise. Role: Selected actual biopsy mechanism, consent and harm categories; no pause rules. |
| Royal Papworth actual audited2024–25 accounts; dated reporting period | Own2024–25 audited notes identify public commissioner, private-patient, research/education and charitable income; research strategy acknowledges industry collaboration. Current2025–26 report not yet linked in actual report index. Complete donors, leaflet allocation and contributor/trial chains unclosed. | United Kingdom; actual Royal Papworth address Cambridge Biomedical Campus, Cambridge, England. Local provider procedure context. | Tier 3 audited institutional financial self-disclosure. | B provisional for explicitly dated financial routes. Statutory scrutiny supports checking; institution self-report and current allocation gaps remain. Provenance only. |
| Royal Papworth actual report index;2025–26 annual report not yet linked | Actual report index says2025–26 annual report will be published shortly;2024–25 accounts available separately. Index is not the unposted current financial ledger. | United Kingdom; actual Royal Papworth address Cambridge Biomedical Campus, Cambridge, England. Local provider procedure context. | Tier 3 institutional publication/status self-disclosure. | B provisional for actual report-access status and Cambridge contact; future publication and full ledger not inferred. Provenance only. |
| NCCIH St John’s wort, May2025; selected medicine interactions | See separate appropriations and gift-route rows. Exact education allocation, named reviewer outside interests and original supplement-trial chains unclosed. | United States; NIH/NCCIH Bethesda, Maryland; retail-product origin not inferred. | Tier 1 public education route, provisional; original-trial independence unclassified. | B provisional — actual2025 selected interaction/cardiac warning body read. Public safety/accuracy incentives; full named reviewer/underlying-study chains unclosed. Therapeutic efficacy, generic safety assurances and safe-exposure quotas excluded. Role: Selected immunosuppressant interaction warning. |
| Actual NCCIH appropriations history through FY2024; not a FY2026 total | Actual appropriation history ends FY2024; not current FY2026 spending or page allocation. | United States; NCCIH/NIH Bethesda, Maryland. Donor, supplier and underlying-study jurisdictions unclosed. | Tier 3 institutional financial self-report. | B provisional — actual appropriation/gift original read, with period limits. Public accountability and resource incentives; full named receipts and allocations unclosed. Finance only. Role: Actual dated institutional appropriations. |
| Actual NCCIH separate Gift Fund, conditional research gifts and Bethesda contact | Actual separate Gift Fund accepts donations/bequests, unconditional support or designated research gifts. Current named donor receipts, outside commercial contributors and page allocation unclosed. | United States; NCCIH/NIH Bethesda, Maryland. Donor, supplier and underlying-study jurisdictions unclosed. | Tier 3 institutional financial self-report. | B provisional — actual appropriation/gift original read, with period limits. Public accountability and resource incentives; full named receipts and allocations unclosed. Finance only. Role: Actual gift authority and allocation gap. |
| NHS angina, March18,2025; selected emergency warnings | See separate national website policy and institution finance rows. Exact page/contributor and original-trial chains unclosed. | United Kingdom; national England education. Provider finances and other jurisdictions separate. | Tier 1 public education route, provisional; original-trial independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page/author and underlying trial chains unclosed. No personal dose or outcome estimate. Role: Selected emergency chest-pain warning. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed | Separate NHSBT institution: see own audited accounts. Contributor payments, page allocation and original-study chains unclosed; national NHS finances do not substitute. Actual overview identifies BTS collaboration and indexed financial context; direct BTS originals inaccessible. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 2 public/professional-partner education, provisional; contributor and original-trial finance unclassified. | C provisional — actual selected original read; clinical revision date unclosed. Specialist accuracy incentives, local service priorities, simplification and financial gaps remain. Attributed care context, no quantified efficacy or harm rate. Role: Actual joint educational scope, no whole-author clearance. |
| NHSBT actual audited2025–26 annual report and accounts, July2026 | Own2025–26 audited notes: service fees, public funding, university/commercial research and trial contracts, and non-NHS income. Organ-transplant DHSC grant-in-aid is General Fund/equity rather than operating income; devolved administrations contribute. Charity/corporate partnerships acknowledged. Exact page, full backer and contributor allocation unclosed. | United Kingdom; NHSBT institutional contact separately traced. Local transplant-centre pathways differ. | Tier 3 institutional audited financial self-disclosure. | B provisional for explicitly dated institutional financial routes. Statutory scrutiny supports checking; institutional reporting interests and incomplete allocations remain. Financial provenance only. |
| NHSBT actual Bristol head-office contact | Own contact identifies head office in Filton, Bristol. See separate accounts for funding; location is not a donor or trial audit. | United Kingdom; actual Filton, Bristol, England head office. | Tier 3 institutional contact self-disclosure. | B provisional for actual institutional location; full financial chains unclosed. Provenance only. |
| BTS official2026 corporate scheme, indexed original; direct access failed | Official indexed2026 corporate scheme lists paid sponsorship, additional congress symposia and sponsored fellowships; official indexed partner list includes Astellas, Chiesi and other relevant pharmaceutical/device businesses. Direct originals returned403; ordinary public fetch failed DNS. Complete audited income, named contributor interests and page-specific allocation were not retrieved; no sponsorship of a particular NHSBT page is inferred. | United Kingdom professional society; complete current legal headquarters, sponsor corporate chains and manufacturing jurisdictions not cleared in this focused audit. | Tier 3 society financial/partner self-disclosure, access-limited; sponsor-origin product promotion Tier4/D excluded. | C provisional for attributed indexed-original funding context, explicitly not full-page access or clean clinical independence. Sponsor visibility and professional education interests remain; no efficacy, product testimonial or precise sponsorship amount adopted. Role: Explicit indexed-only society commercial route. |
| BTS official2026 partner listing, indexed original; direct access failed | Official indexed2026 corporate scheme lists paid sponsorship, additional congress symposia and sponsored fellowships; official indexed partner list includes Astellas, Chiesi and other relevant pharmaceutical/device businesses. Direct originals returned403; ordinary public fetch failed DNS. Complete audited income, named contributor interests and page-specific allocation were not retrieved; no sponsorship of a particular NHSBT page is inferred. | United Kingdom professional society; complete current legal headquarters, sponsor corporate chains and manufacturing jurisdictions not cleared in this focused audit. | Tier 3 society financial/partner self-disclosure, access-limited; sponsor-origin product promotion Tier4/D excluded. | C provisional for attributed indexed-original funding context, explicitly not full-page access or clean clinical independence. Sponsor visibility and professional education interests remain; no efficacy, product testimonial or precise sponsorship amount adopted. Role: Explicit indexed-only named partner context. |
| ISHLT actual2026 commercial-support prospectus | Actual2026 prospectus offers paid industry webinar, symposium, branding and communication promotion. Industry-produced recordings are explicitly distinguished from official education. Offered support is not proof that a particular company paid for the recipient guideline; full audited society income unclosed. | United States; actual Foundation contact Chicago, Illinois. International professional remit; complete society legal and sponsor jurisdictions unclosed. | Tier 3 institutional commercial/charitable self-disclosure. | B provisional for actual stated revenue routes/contact; C if used to certify clinical independence. Reputation, fundraising and promotion incentives remain; full audited ledger and allocations unclosed. Financial context only. |
| ISHLT Foundation actual2025 impact and donor report | Actual2025 Foundation report lists individual and organizational philanthropy, including an attributed Natera partnership account. Impact/donor report is not a complete audited society ledger. Exact guideline allocation, contracts and full donor ownership chains unclosed. | United States; actual Foundation contact Chicago, Illinois. International professional remit; complete society legal and sponsor jurisdictions unclosed. | Tier 3 institutional commercial/charitable self-disclosure. | B provisional for actual stated revenue routes/contact; C if used to certify clinical independence. Reputation, fundraising and promotion incentives remain; full audited ledger and allocations unclosed. Financial context only. |
| ISHLT Foundation actual industry-partner route and Chicago contact | Own Foundation page acknowledges industry philanthropy for research, education and related programmes. Actual footer identifies Chicago, Illinois contact. Exact donors represented only by image logos were not cleared from extracted text; no particular guideline sponsorship inferred. | United States; actual Foundation contact Chicago, Illinois. International professional remit; complete society legal and sponsor jurisdictions unclosed. | Tier 3 institutional commercial/charitable self-disclosure. | B provisional for actual stated revenue routes/contact; C if used to certify clinical independence. Reputation, fundraising and promotion incentives remain; full audited ledger and allocations unclosed. Financial context only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
Frequently asked questions
Does rejection prove I missed medicines? No. It can occur despite careful medicine use.
Can rejection be detected when I feel well? Planned surveillance can identify problems before obvious symptoms.
What is AMR? Antibody-mediated rejection; its assessment and treatment differ from a simple symptom label.
Does a biopsy treat rejection? It supplies tissue information for diagnosis and care decisions.
Can I use an online steroid dose? No. Obtain the transplant team’s instructions.
What if I cannot keep medicines down? Contact the transplant team promptly; do not invent a replacement or extra-dose plan.
Sources and funding notes
- NHSBT rejection explanation and surveillance; clinical date unclosed — Selected rejection definition and type-specific treatment context.
- NHSBT transplant warning signs; clinical date unclosed — Selected symptom reporting and surveillance context.
- NHSBT selected long-term complication context; clinical date unclosed — Selected late-rejection, illness and long-term monitoring context.
- NHSBT selected transplant-medicine roles and cautions; clinical date unclosed — Selected immunosuppressant handling, harms and review.
- NHSBT selected care at home after transplantation; clinical date unclosed — Selected individualized medicine and recovery support.
- NHSBT selected ongoing lifestyle and prevention context; clinical date unclosed — Selected healthy-living support; no rejection prevention guarantee.
- NHSBT selected infection explanation; clinical date unclosed — Selected immunosuppression/infection distinction; no antibiotic duration or rare-harm reassurance.
- NHSBT cardiac allograft vasculopathy explanation; clinical date unclosed — Selected long-term vascular distinction.
- ISHLT recipient guideline, 2023; actual141-page original and disclosures — Selected surveillance, antibody/pathology interpretation and variable AMR framework.
- Royal Papworth actual12-page cardiac-biopsy guide, October2025 version2; internal review-date discrepancy — Selected actual biopsy mechanism, consent and harm categories; no pause rules.
- Royal Papworth actual audited2024–25 accounts; dated reporting period — Actual separately dated provider financial routes.
- Royal Papworth actual report index;2025–26 annual report not yet linked — Actual current annual-report access gap.
- NCCIH St John’s wort, May2025; selected medicine interactions — Selected immunosuppressant interaction warning.
- Actual NCCIH appropriations history through FY2024; not a FY2026 total — Actual dated institutional appropriations.
- Actual NCCIH separate Gift Fund, conditional research gifts and Bethesda contact — Actual gift authority and allocation gap.
- NHS angina, March18,2025; selected emergency warnings — Selected emergency chest-pain warning.
- NHS England actual audited2025–26 accounts — Actual separate national NHS institutional accounts.
- NHSBT heart-transplant overview and BTS collaboration; clinical date unclosed — Actual joint educational scope, no whole-author clearance.
- NHSBT actual audited2025–26 annual report and accounts, July2026 — Actual separate institutional funding routes.
- NHSBT actual Bristol head-office contact — Actual NHSBT head-office location.
- BTS official2026 corporate scheme, indexed original; direct access failed — Explicit indexed-only society commercial route.
- BTS official2026 partner listing, indexed original; direct access failed — Explicit indexed-only named partner context.
- ISHLT actual2026 commercial-support prospectus — Actual separate industry-support offerings.
- ISHLT Foundation actual2025 impact and donor report — Actual philanthropy and donor-report context.
- ISHLT Foundation actual industry-partner route and Chicago contact — Actual Foundation funding route/contact.
- NHS national website funding policy — Financial provenance only.
The selected clinical originals and institutional financial sources were opened, with access-limited author reports and corrections identified explicitly. Actual NHSBT selected clinical originals and own2025–26 audited accounts/contact read; clinical revision dates, named-contributor payments and page allocation unclosed. Its overview identifies BTS collaboration; official indexed corporate/partner disclosures retained with direct-access failure explicitly stated. Actual141-page2023 ISHLT recipient guideline selected surveillance/CAV/rejection sections and printed e117 finance/author disclosures read. No development/preparation support reported does not clear relevant author relationships or original drug/diagnostic trials. Actual2026 commercial prospectus and2025 Foundation donor report/industry route opened; no full current audited society ledger or source-specific sponsorship inferred. Attributed specialist frameworks, not a complete current medicine/diagnostic menu or independent efficacy estimate. No personal dose, biopsy/imaging interval, result threshold, medicine interruption or transplant eligibility rule. Actual12-page Royal Papworth October2025 version2 cardiac-biopsy original selected mechanism, consent and harm sections read. Footer review2027 conflicts with consent-page October2025 review field; personal anticoagulant/diuretic pauses, rates and recovery promises excluded. Own193-page2024–25 audited financial notes and current report index read;2025–26 annual financial report not yet linked. Provider funds and contributor/page allocation kept separate. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.